Literature DB >> 22038404

Molecular signature of a public clonotypic autoantibody in primary Sjögren's syndrome: a "forbidden" clone in systemic autoimmunity.

Rhianna Lindop1, Georgia Arentz, Tim K Chataway, Lauren A Thurgood, Michael W Jackson, Joanne H Reed, James McCluskey, Tom P Gordon.   

Abstract

OBJECTIVE: This study was undertaken to determine the molecular characteristics of clonotypic autoantibodies in the sera of patients with primary Sjögren's syndrome (SS). This characterization is hampered by the presence of mixed anti-Ro/La specificities that may conceal clonotypic species. In order to narrow clonotypic diversity, a positive selection step was performed on a peg-like determinant of Ro 60 (termed Ro 60-peg) prior to analysis of the autoantibody proteome.
METHODS: Monospecific anti-Ro 60-peg IgG were isolated by affinity purification from the sera of 7 patients with primary SS and anti-Ro/La and subjected to 2-dimensional gel electrophoresis and high-resolution orbitrap mass spectrometric sequencing. V regions of heavy and light chains were analyzed by combined database and de novo amino acid sequencing.
RESULTS: Proteomic analysis revealed a Ro 60-peg-specific IgG1κ-restricted monoclonal autoantibody that was present in the sera of all patients and specified by a V(H) 3-23 heavy chain paired with a V(κ) 3-20 light chain. The public anti-Ro 60-peg clonotype was specified further by common mutations in the heavy-chain and light-chain complementarity-determining regions. Titers and relative affinities of clonotypic IgG did not vary over the course of the disease.
CONCLUSION: The expression of a Ro 60-reactive public B cell clonotype in a subset of patients with primary SS as a long-lived, class-switched circulating autoantibody implies a common breach of B cell tolerance checkpoints in these patients. The unique heavy chain/light chain signature opens the possibility of tracking the development of a "forbidden" clone against a bona fide systemic autoantigen in human disease.
Copyright © 2011 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22038404     DOI: 10.1002/art.30566

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  9 in total

1.  An immunodominant La/SSB autoantibody proteome derives from public clonotypes.

Authors:  L A Thurgood; G Arentz; R Lindop; M W Jackson; A F Whyte; A D Colella; T K Chataway; T P Gordon
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

2.  Molecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response.

Authors:  Yariv Wine; Daniel R Boutz; Jason J Lavinder; Aleksandr E Miklos; Randall A Hughes; Kam Hon Hoi; Sang Taek Jung; Andrew P Horton; Ellen M Murrin; Andrew D Ellington; Edward M Marcotte; George Georgiou
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

Review 3.  Advances in understanding the pathogenesis of primary Sjögren's syndrome.

Authors:  Gaëtane Nocturne; Xavier Mariette
Journal:  Nat Rev Rheumatol       Date:  2013-07-16       Impact factor: 20.543

4.  Lupus anti-ribosomal P autoantibody proteomes express convergent biclonal signatures.

Authors:  M A Al Kindi; A D Colella; D Beroukas; T K Chataway; T P Gordon
Journal:  Clin Exp Immunol       Date:  2016-01-29       Impact factor: 4.330

5.  Precipitating anti-dsDNA peptide repertoires in lupus.

Authors:  J J Wang; A D Colella; D Beroukas; T K Chataway; T P Gordon
Journal:  Clin Exp Immunol       Date:  2018-10-11       Impact factor: 4.330

Review 6.  B cells in the pathogenesis of primary Sjögren syndrome.

Authors:  Gaëtane Nocturne; Xavier Mariette
Journal:  Nat Rev Rheumatol       Date:  2018-02-08       Impact factor: 20.543

7.  Gut and Liver B Cells of Common Clonal Origin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease.

Authors:  Brian K Chung; Eva Kristine Klemsdal Henriksen; Kristin Kaasen Jørgensen; Tom H Karlsen; Gideon M Hirschfield; Evaggelia Liaskou
Journal:  Hepatol Commun       Date:  2018-08-06

Review 8.  An Immunoproteomic Survey of the Antibody Landscape: Insights and Opportunities Revealed by Serological Repertoire Profiling.

Authors:  Steven Ionov; Jiwon Lee
Journal:  Front Immunol       Date:  2022-02-01       Impact factor: 7.561

9.  Persistence and selection of an expanded B-cell clone in the setting of rituximab therapy for Sjögren's syndrome.

Authors:  Uri Hershberg; Wenzhao Meng; Bochao Zhang; Nancy Haff; E William St Clair; Philip L Cohen; Patrice D McNair; Ling Li; Marc C Levesque; Eline T Luning Prak
Journal:  Arthritis Res Ther       Date:  2014-02-11       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.